Drug: avelumab (Merck/Pfizer)
Status: A review has been submitted for the proposed use of the investigational immunotherapy in patients with metastatic Merkel cell carcinoma (MCC).
Significant Trial Data:
- Submission is supported by data from JAVELIN Merkel 200, a multicenter, single-arm, open-label, Phase II study of 88 patients with metastatic MCC, whose disease had progressed after at least one chemotherapy treatment.
- The JAVELIN Merkel 200 study represents the largest data set of any